Skip to main content
Log in

Non-additive positive inotropic effects of amrinone and ouabain on cat papillary muscles

  • Originals
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Amrinone has been shown to produce haemodynamic benefits in digitalis-treated patients. Since amrinone is a positive inotropic agent on isolated heart muscle, these benefits may mean that amrinone increases the maximal ouabain-induced increase in force of contraction, without causing toxicity. We have therefore measured, in cat right ventricular papillary muscles, the inotropic effects of ouabain, amrinone alone and amrinone with a maximally effective, non-toxic ouabain concentration (2×10−7 M). Ouabain is much more potent than amrinone (EC50-values: ouabain, 8×10−8 M, amrinone, 1–2.8×10−3 M). The highest amrinone concentration used (6×10−3 M) produced a significantly lower increase in force of contraction than ouabain (2×10−7 M) in the same muscles. After ouabain (2×10−7 M) produced a stable effect, no further increase in force of contraction was observed with any amrinone concentration. Sustained arrhythmias were observed in five of six muscles at 3×10−3 M amrinone with ouabain (2×10−7 M), but in only one of these muscles with amrinone 3×10−3 M alone. Since the positive inotropic effects of amrinone are not additive with those from a maximally effective ouabain concentration, the haemodynamic benefits seen in patients are probably due to non-cardiac effects of amrinone such as vasodilatation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Adams HR, Rhody J, Sutko JL (1982) Amrinone activates K+-depolarized atrial and ventricular myocardium of guinea pigs. Circ Res 51:662–665

    Google Scholar 

  2. Alousi AA, Farah AE, Lesher GY, Opalka CJ Jr (1979) Cardiotonic activity of amrinone — Win 40680 (5-amino-3.4′-bipyridin-(1H)-one). Circ Res 45:666–677

    Google Scholar 

  3. Bayliss J, Norell M, Canepa-Anson R, Reuben SR, Poole-Wilson PA, Sutton GC (1983) Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. Br Heart J 49:214–221

    Google Scholar 

  4. Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi AA (1978) Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med 299:1373–1377

    Google Scholar 

  5. Binah O, Legato MJ, Danilo P Jr, Rosen MR (1983) Developmental changes in the cardiac effects of amrinone in the dog. Circ Res 52:747–752

    Google Scholar 

  6. Brown L, Erdmann E (1984) Comparison of the affinity of human, beef and cat heart (Na++K+)-ATPase for different digitalis derivatives. Arzneim Forsch, in press

  7. Canepa-Anson R, Dawson JR, Frankl WS, Kuan P, Sutton GC, Reuben S, Poole-Wilson PA (1982) Beta2 adrenoceptor agonists. Pharmacology, metabolic effects and arrhythmias. Eur Heart J 3(supp D):129–134

    Google Scholar 

  8. Conrad KA, Prosnitz EH (1981) Cardiovascular effects of theophylline. Partial attenuation by beta blockade. Eur J Clin Pharmacol 21:109–114

    Google Scholar 

  9. Endoh M, Yamashita S, Taira N (1982) Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharmacol Exp Ther 221:775–783

    Google Scholar 

  10. Gaide MS, Fitterman WS, Wiggins JR, Myerburg RJ, Cameron JS, Bassett AL (1983) Amrinone relaxes potassium-induced contracture of failing right ventricular muscle of cats. J Cardiovasc Pharmacol 5:335–340

    Google Scholar 

  11. Gilman AG, Goodman LS, Gilman A (1980) The pharmacological basis of therapeutics. 6th edition. Macmillan, New York, pp 729–760

    Google Scholar 

  12. Honerjäger P, Schäfer-Korting M, Reiter M (1981) Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence. Naunyn-Schmiedeberg's Arch Pharmacol 318:112–120

    Google Scholar 

  13. LeJemtel TH, Keung E, Ribner HS, Davis R, Wexler J, Blaufox MD, Sonnenblick EH (1980) Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. Am J Cardiol 45:123–129

    Google Scholar 

  14. LeJemtel TH, Keung E, Sonnenblick EH, Ribner HS, Matsumoto M, Davis R, Schwartz W, Alousi AA, Davolos D (1979) Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circulation 59:1098–1104

    Google Scholar 

  15. Kariya T, Wille LJ, Dage RC (1982) Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043. J Cardiovasc Pharmacol 4:509–514

    Google Scholar 

  16. Millard RW, Dubé G, Grupp G, Grupp I, Alousi A, Schwartz A (1980) Direct vasodilator and positive inotropic actions of amrinone. J Mol Cell Cardiol 12:647–652

    Google Scholar 

  17. Miller RR, Vismara LA, Williams DO, Amsterdam EA, Mason DT (1976) Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Differential effects of nitroprusside, phentolamine and nitroglycerin on cardiac function and peripheral circulation. Circ Res 39:127–133

    Google Scholar 

  18. Ogilvie RI, Fernandez PG, Winsberg F (1977) Cardiovascular response to increasing theophylline concentrations. Eur J Clin Pharmacol 12:409–414

    Google Scholar 

  19. Onuaguluchi G, Tanz RD (1981) Cardiac effects of amrinone on rabbit papillary muscle and guinea pig Langendorff heart preparations. J Cardiovasc Pharmacol 3:1342–1355

    Google Scholar 

  20. Robinson PJ, Lvoff R, Chong B, Barrett PA (1981) Amrinone — a new inotropic agent in chronic resistant congestive cardiac failure. Aust NZ J Med 11:666–668

    Google Scholar 

  21. Siegel LA, Keung E, Siskind SJ, Forman R, Feinberg H, Strom J, Efstathakis D, Sonnenblick EH, LeJemtel TH (1981) Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure. Circulation 63:838–844

    Google Scholar 

  22. Ward A, Brogden RN, Heel RC, Speight TM, Avery GS (1983) Amrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 26:468–502

    Google Scholar 

  23. Wilmshurst PT, Thompson DS, Jenkins BS, Coltart DJ, Webb-Peploe MM (1982) Effect of intravenous amrinone on resting haemodynamic function in patients with congestive heart failure. Br Heart J 48:93

    Google Scholar 

  24. Wilmshurst PT, Thompson DS, Miles CM, Juul SM, Jenkins BS, Coltart DJ, Webb-Peploe MM (1983) Comparison of effects of amrinone and nitroprusside in heart failure. Circulation 68 (supp III):127

    Google Scholar 

  25. Wynne J, Malacoff RF, Benotti JR, Curfman GD, Grossman W, Holman BL, Smith TW, Braunwald E (1980) Oral amrinone in refractory congestive heart failure. Am J Cardiol 45:1245–1249

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by the DFG (Er 65/4-3)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, L., Erdmann, E. Non-additive positive inotropic effects of amrinone and ouabain on cat papillary muscles. Klin Wochenschr 62, 390–393 (1984). https://doi.org/10.1007/BF01742294

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01742294

Key words

Navigation